Canadian Respiratory Research Network
The Canadian Respiratory Research Network (CRRN), in close partnership with the Canadian Lung Association and other partners, will improve patient care and outcomes through the creation of an enduring national network of investigators and research platforms. The network will enable innovative, collaborative, respiratory health research that influences decision making and ensures high quality training and career development of a new generation of investigators.
Health burden addressed
The Canadian Respiratory Research Network will focus on chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma, which together affect almost 15% of Canadians. Overall, chronic lung disease accounts for more than 6% of annual health-care costs in Canada, and COPD is the leading cause of hospitalization. A large number of Canadians with COPD and asthma also remain undiagnosed. As the network matures, other lung diseases such as cystic fibrosis and neonatal lung disease will be studied.
The Canadian Respiratory Research Network will bring researchers across disciplines together to improve our understanding of the origins and progression of chronic lung diseases in Canada. Research objectives include:
- Identifying novel risk factors (such as air pollution and poor control of lung disease during pregnancy and childhood) that may contribute to the origins and progression of chronic lung disease.
- Discovering novel biomarkers in blood and sputum that may help us understand and control chronic lung disease.
- Investigating the health and economic burden of undiagnosed asthma and COPD in Canada.
|Name||Role in CRRN||Main Affiliation|
|Dr. Shawn Aaron||Director||Senior Scientist at the Ottawa Hospital Research Institute, Head of the Division of Respiratory Medicine at The Ottawa Hospital, Professor of Medicine at the University of Ottawa|
|Dr. James Martin||Co-Director||Professor of Medicine and Chairman of the Department of Medicine, McGill University|
|Dr. Denis O'Donnell||Theme Leader (Physiology)||Queen's University|
|Dr. Grace Parrage||Theme Leader (Imaging)||University of Western Ontario|
|Dr. Don Sin||Theme Leader (Biomarker Discovery)||University of British Columbia|
|Dr. Chris Carlsten||Theme Leader (Air Pollution Exposure Studies)||University of British Columbia|
|Dr. Andrew Halayko||Theme Co-Leader (Basic Science and Discovery + Training and Development||University of Manitoba|
|Dr. Martin Stampfli||Theme Co-Leader (Basic Science and Discovery)||McMaster University|
|Dr. Mohsen Sadatsafavi||Theme Leader (Health Economics)||University of British Columbia|
|Dr. Francine Ducharme||Theme Leader (Pharmaco-Epidemiology)||University of Montreal|
|Dr. Andrea Gershon||Theme Leader (Population Health)||University of Toronto|
|Dr. Teresa To||Theme Leader (Environmental Health)||University of Toronto|
|Dr. Jean Bourbeau||Theme Co-Leader (Cohort Studies)||McGill University|
|Dr. Wan Tan||Theme Co-Leader (Cohort Studies)||University of British Columbia|
|Dr. Samir Gupta||Theme Co-Leader (Knowledge Translation)||University of Toronto|
|Dr. Louis-Philippe Boulet||Theme Co-Leader (Knowledge Translation)||Laval University|
|Dr. Ian Graham||Theme Co-Leader (Knowledge Translation)||Ottawa Hospital Research Institute|
|Michelle McEvoy||Coordinator of Training, Development and Knowledge Transfer||Canadian Lung Association|
|Katherine Vandemheen||Coordinator of Network Research Programs||Ottawa Hospital Research Institute|
- Canadian Institutes of Health Research: $4,350,000
- Canadian Lung Association: $1,085,000
- Boehringer Ingelheim (Canada) Ltd.: $568,000
- AstraZeneca: $550,000
- GSK: $550,000
- Novartis Pharmaceuticals Canada Inc.: $250,000
- British Columbia Lung Association: $200,000
- Date modified: